Skip to content

Company information lookup

INNATE IMMUNOTHERAPEUTICS LIMITED (IIL)

Development of a drug candidate to treat secondary progressive multiple sclerosis.

On this page you will find:

Delayed share price
Company announcements
Price history chart
Exchange Traded Options
ASX-Listed Emblem Company details
Closing prices
Dividends
Warrants & Structured Products
ASX CFDs

Delayed share price

Prices are delayed by 20 minutes unless stated otherwise in the Conditions. Retrieving any price indicates your acceptance of the Conditions.

Code Last % Chg Bid Offer Open High Low Vol
IIL 0.240 0% 0.230 0.240 0.240 0.245 0.240 72,854

INNATE IMMUNOTHERAPEUTICS LIMITED details

Please note: ASX relies on third parties to provide the information contained in the company details table, and therefore is unable to assume any responsibility for the accuracy or timeliness of the information.

Issuer Code IIL
Securities
Official Listing Date 23 December, 2013
GICS Industry Group Pharmaceuticals & Biotechnology
Exempt Foreign? No
Internet Address http://www.innateimmuno.com
Registered Office Address Suite 4.01, 35 Lime Street, SYDNEY, NSW, AUSTRALIA, 2000
Head Office Telephone (02) 8003 3650
Head Office Fax (02) 9225 5050
Share Registry COMPUTERSHARE INVESTOR SERVICES PTY LIMITED
YARRA FALLS, 452 JOHNSTON STREET, ABBOTSFORD, VIC, AUSTRALIA, 3067
Share Registry Telephone 1300 787 272
Directors / Senior Management
Mr Michael Quinn (Non Exec. Chairman)
Mr Simon Wilkinson (Managing Director)
Mr Christopher Collins (Non Exec. Director)
Ms Elizabeth Hopkins (Non Exec. Director)
Mr Andrew Sneddon (Non Exec. Director)
Mr Jeff Carter (CFO)
Company Secretary Mr Andrew John Cooke
Principal Activities Development of a drug candidate to treat secondary progressive multiple sclerosis.

INNATE IMMUNOTHERAPEUTICS LIMITED announcements

How are company announcements published on www.asx.com.au?

Date Price
sens.
Headline Pages PDF
21/08/2014   Results of Meeting - AGM 2 PDF
20/08/2014   CEO Address to AGM 11 PDF
20/08/2014   Chairman's Address to Shareholders - AGM 2 PDF
19/08/2014   Phase 2B WANRI Ethics Approval 2 PDF
29/07/2014 asterix Appendix 4C - June 2014 Quarterly Cash Flow Report 6 PDF
21/07/2014   Use of Funds Consistent with Business Objectives 1 PDF
18/07/2014   Annual Report to shareholders 68 PDF
18/07/2014   Notice of Annual General Meeting/Proxy Form 6 PDF
20/06/2014 asterix Update on Phase 2B Trial of MIS416 2 PDF
18/06/2014 asterix Compassionate Use Programme Update 2 PDF

> search for past company announcements

Viewing Market Announcements:
Users of Adobe Acrobat Reader version 6.0.0 may have difficulty accessing PDF announcements. Symptoms include slow downloads, blank documents, and small white boxes appearing in the PDF. We recommend you download the latest version of the free Adobe Acrobat Reader. To check which version you have, open Adobe Acrobat Reader, click on 'Help', then click 'About Adobe Reader 6.0'.

Closing prices

Closing prices are displayed for the last 5 days on which the security traded on ASX within the last 6 months.

Date Last % Change High Low Vol *
01 Sep 2014 0.240 0% 0.240 0.240 14,259
29 Aug 2014 0.240 -4% 0.250 0.240 92,222
28 Aug 2014 0.250 4.17% 0.250 0.240 68,000
27 Aug 2014 0.240 0% 0.240 0.240 140,824
26 Aug 2014 0.240 4.35% 0.240 0.235 31,390

* Volume of shares shown represents only those shares traded on ASX.

INNATE IMMUNOTHERAPEUTICS LIMITED price history chart

* More charting options are available.

Dividends

How are dividends released on www.asx.com.au?

No dividends have been found for the security IIL. This is likely to be because a dividend has not been announced to the ASX by this company during the specified timeframe or a dividend has been announced but is not yet available on this website.

Exchange Traded Options

No Exchange Traded Options are available over the security IIL

Warrants & Structured Products

No warrants & Structured Products are available over the security IIL

ASX CFDs

No Contracts For Differences are available over the security IIL